Astellas Ramps up M&A, Buys U.S. Biotech Xyphos for as Much as $665M
Astellas Pharma Inc (4503.T) has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million including potential development milestones and its second acquisition announced this month. Japan’s second biggest drugmaker by sales paid $120 million upfront for Xyphos and the rest will be milestone payments, the companies said […]
Astellas Ramps up M&A, Buys U.S. Biotech Xyphos for as Much as $665M Read More »
